Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.45 |
| ▸ | RELA | Q04206 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83962 | 0.86 | GAA (0.47) | GAANFKB1NFKB2RELACTSK | |
| SCHEMBL14468801 | 0.86 | GAA (0.47) | GAANFKB1NFKB2RELACTSK | |
| SCHEMBL13485277 | 0.85 | ALDH1A1 (0.49) | GAAKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13485309 | 0.85 | ALDH1A1 (0.49) | GAAKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28601656 | 0.81 | GAA (0.48) | GAANFKB1NFKB2RELAKMT2A | |
| SCHEMBL4703211 | 0.81 | GAA (0.48) | GAANFKB1NFKB2RELAKMT2A | |
| SCHEMBL4699843 | 0.81 | GAA (0.48) | GAANFKB1NFKB2RELAKMT2A | |
| SCHEMBL28601660 | 0.81 | GAA (0.48) | GAANFKB1NFKB2RELAKMT2A | |
| SCHEMBL9906478 | 0.81 | GAA (0.45) | GAANFKB1NFKB2RELAALDH1A1 | |
| SCHEMBL23894828 | 0.80 | CYP1A2 (0.43) | GAAKDM4EALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198276-B2 | Kinase inhibitor compounds | XCOVERY HOLDING COMPANY LLC (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100144768-A1 | KINASE INHIBITOR COMPOUNDS | COMPASS HORIZON FUNDING COMPANY LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2008153942-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144768-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K9, MAP3K1, MAP3K8 | GAA 1840/4885NFKB1 663/4885NFKB2 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.